Locken hier 300% in kurzer Zeit??Ich bin mir sicher!!!! - 500 Beiträge pro Seite

Gestern um ca. 20:30 Uhr deutscher Zeit gab es eine bahnbrechende Meldung für SIGA.Sie bekamen die Zulassung für Ihr Smallpox-Drug - Siga-246 durch die FDA.

Ich glaube das viel der Amis erst nach Börsenschluß diese Nachricht gelesen haben oder gar erst heute vor Börsenbeginn in den USA lesen werden.Deswegen rechne ich mit stark weiter steigenden Kursen in den nächsten Tagen.

SIGA hat gerade mal eine MK beim gestrigen Shclußkurs in den USA von gut 153 Millionen Dollar.Lächerlich nach der Zulassung durch die FDA.

Eine MK von 500-700 Millionen Dollar wäre gerechtfertigt finde ich und deswegen lautet mein Kusrziel innerhalb der nächsten 6 Monate auch 15-23 Dollar.


Hier die gestrige NEWS:


December 20, 2006 - 2:30 PM EST


FDA Approves Orphan Drug Designation for SIGA's Smallpox Drug, SIGA-246

SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that the Office of Orphan Products Development (OOPD) of the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIGA-246, SIGA's smallpox drug, for the prevention and treatment of smallpox. In December 2005, the FDA awarded SIGA-246 fast track status to expedite the drug's review.

Orphan Drug designation will entitle SIGA to seven years of marketing exclusivity in the United States if SIGA-246 becomes the first drug of its kind to obtain marketing approval from the FDA. Historically, the approval time for orphan products as a group has been considerably shorter than the approval time for other drugs.

"This is an important step in bringing SIGA-246 to market. The drug has made significant progress since the approval of its Investigational New Drug application just a year ago. In July 2006, we successfully completed the first planned human clinical safety trial, and, in October, the drug demonstrated 100% protection against human smallpox virus in a primate trial. We believe that SIGA-246 holds great promise and will be the first drug available to prevent and treat the disease without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Smallpox has been designated by the Department of Homeland Security as a "material threat" to our national security, qualifying SIGA -246 for purchase for the Strategic National Stockpile under Project Bioshield. Currently, there is no effective and safe smallpox therapy available without the risk of significant complications, and the U.S. government has expressed strong interest in the development of novel smallpox therapies. Existing techniques to prevent or ameliorate smallpox have unacceptably high rates of complications, including encephalitis, myocarditis and death, and can take days or weeks to confer protection.


Also Leute handelt bevor Ihr wieder mal hinterherschauen müßt.


Hier noch ein interessanter Link:

http://adventfinancialinc.com/research_r...



Viel Glüc allen.

Amis haben die Nachricht direkt um 15Uhr durchgekaut, darauf stieg
sie dann 82%

Antwort auf Beitrag Nr.: 26.366.652 von luto9 am 21.12.06 11:27:34Ich weiß zwar nicht wo Du die Dinge her holst aber die NEWS kam erst um 20:30 Uhr und darauf hin hat die Aktie auch erst reagiert.

Also hier wurde nichts um 15:00 Uhr gestriger Zeit durchgekaut.


Schau auf den Chart und Du wirst sehen seit wann die AMIS bescheid wissen:

Antwort auf Beitrag Nr.: 26.366.843 von Kaufrausch1 am 21.12.06 11:36:30sorry meinte natürlich drüben, also 3: pm

Hier noch mal ein Link zu den letzten NEWS von SIGA Techn.


Am 19.10.2006 gab es ein Privat Placement von 9 Millionen Dollar.

http://www.siga.com/1c_PressReleases.html

Antwort auf Beitrag Nr.: 26.367.120 von invest2002 am 21.12.06 11:49:29jetzt noch rein?

Aktueller Kurs in Frankfurt ist 3,83 Euro dies entspricht einen US-Kurs von 5,04 Dollar.


Also ein moderater Aufschlag von gerade mal 1,8%.


Schaut heute mittag mal auf den Kurs.Ich glaube nicht das es an diesem Tag ein Minuszeichen geben wird womit anscheinend einige hier rechnen.


Diese Woche noch 8 Dollar denke ich.

Note the Target: $10.20 per share...


... and that was the target in the next 9 months. After SIGA begins shipping product to the $5 billion market, the target price will certainly rise significantly. Significantly.


Nur eine Meinung aus den USA.Aber nicht unbegründet siehe PDF Dokument:


http://adventfinancialinc.com/research_r...

300 % sind doch immer eine sichere sache

Antwort auf Beitrag Nr.: 26.369.693 von Taxiert am 21.12.06 13:54:30...ob er den Dreck losgeworden ist?

Hier nochmal die ersten Zeilen aus der Empfehlung:

SIGA Technologies Inc. (NASDAQ: SIGA): Buy
Volatility Risk: High 12-month Price Target: $ 10.20
Analyst: Andre Garnet Report Date: October 25, 2006
research@adventfinancialinc.com
Market Data Fundamental Data
Current Share price (Oct 24, 2006) $3.75 Year End: Dec 31 FY05A FY06E FY07E
52-Week Range $0.86-$5.50 Revenue ($ Million) 8.48 8.12 7.60
Dil. Shares Outstanding (Million) 27.50 Net Margin (%) NM. NM NM

Market Cap. ($ Million) $103.12 EPS (Diluted) ($) (0.09) (0.19) (0.05)
Insider Holdings (%) 32.96 PER (X) NM. NM. NM.
Fiscal Year End Dec P/Sales (X) NM. NM. NM.
Book Value / Share (June 30, 06) $0.03 EV/EBITDA (X) NM. NM. NM.
Investment Update
We raise our rating to Buy from our previous Neutral and set a 12-month Price Target of $10.20
for SIGA following the cancellation of the proposed merger with PharmAthene and the end of the
attendant uncertainties. SIGA Technologies, Inc. (SIGA) is a development-stage biotechnology
company that focuses on the development and commercialization of biodefense products, including
SIGA-246 for treating smallpox infections that has shown promising test results and is about to
begin its final, Phase III trials. We have a positive outlook for revenue growth to be driven by
government purchases of this initial product for which orders could be placed in FY08 and
deliveries begin in FY09. Longer term, we expect purchases of two or three additional products by
government agencies, here and abroad.
Investment Highlights

· We believe that SIGA could begin selling in 2009 the first of several new biopharmaceuticals
intended for protecting against biowarfare agents that include smallpox, the Arenaviruses and
the Ebola virus.

· SIGA and privately held PharmAthene, Inc. have canceled their proposed merger thus ending
the uncertainties that prompted us to issue our previous Neutral recommendation and to
withhold a price target for SIGA.

· The Company’s lead product for treating smallpox infection, SIGA-246, was shown to
provide 100% protection to monkeys infected with a related virus and this product has now
successfully completed its Phase 1 trials.

· We believe that SIGA now has the funding necessary to carry out the one remaining Phase III
trial of SIGA-246 and, assuming it will be successful, to submit an NDA (New Drug
Application) by late 2007 to the FDA, where it will be reviewed in six months or less.

· We think it very likely, therefore, that SIGA-246 will gain approval by the FDA in the first
half of 2008 and that its first commercial shipments could begin in the first half of 2009.

· We raise our recommendation for SIGA to Buy from our previous Neutral and we now set
for it a 12-month Price Target of $ 10.20 instead of our previous No Price Target (see our
September 12, 2006 update). We calculate a risk-adjusted Present Value of $ 9.04 for this
stock, up from our previous $4.50 (see Dec 9, 2005 update).
Update Report
(PLEASE SEE A DISCUSSION OF RISK FACTORS ON PAGES 2 AND 10 AS
WELL AS DISCLAIMERS ON PAGE 16 OF THIS REPORT)
SIGA Technologies, Inc. Advent Financial, Inc
www.adventfinancialinc.com - 2 - October 25, 2006

· Specific Risk Factors:

In our view, SIGA represents a high volatility risk investment
opportunity for investors with above average risk tolerance. Specific risk factors include:
Price Volatility – As it is the case for most development-stage biotechnology companies,
SIGA will have no significant revenues or income before it commercializes a first product.
Until then, it is to be expected that its stock price and trading volume will be largely
news-driven, which contributes to price volatility. Liquidity Risk - As other micro-cap
companies, SIGA has a small trading float and low trading volume, which may contribute to
large spreads and high volatility in its stock price. Technology Risk – New and innovative as
SIGA’s technologies are, they remain unproven and are being used to develop new drugs and
therapies, which are also unproven. Market Risk - For the time being, only the government,
here and abroad, as well as international organizations such as the World Health Organization
(WHO) are potential buyers for the type of biodefense products under development at SIGA.
This may have adverse effects on SIGA’s sales and margins. Intellectual Property
Ownership Risk – It cannot be ruled out that circumstances could arise in which the
government would mandate licensing out or otherwise sharing intellectual property or
technical know-how so as to speed or increase production of specific biodefense products.
This could adversely affect the value of SIGA’s technology as well as its competitive posture
in the biopharmaceuticals industry. Regulatory Risk - Before SIGA’s biodefense products
would be purchased by the government, they will need to be tested for efficacy in animal
studies and for safety in Phase I as well as Phase III human clinical studies. Unless they are
successful in such testing, it is unlikely that any could be sold to the government or to any
other potential buyers. Purchase and Timing Risks – There is no guarantee that the federal
government will eventually purchase some or each of the biodefense products currently being
developed at SIGA and elsewhere, or when and how much of any specific product it will
stockpile.
Although we have factored the risks above into our projections, there can be no assurance
that risks, known or unknown, may come to have an unforeseen effect on the performance of
SIGA and adversely affect the price of its stock.




Der Link: http://adventfinancialinc.com/research_reports/SIGA%20Update…






Ach ja und an meine zwei Vorredner: NEIN ICH BIN NICHT RAUS WOLLTE ES AUCH GAR NICHT.

Solange der Kurs so billig ist stocke ich weiter auf!!!!!!

Eine bomben Zusammenfassung aus den USA von einem Yahoo-Boardteilnehmer:


Big money is involved look:

http://www.hhs.gov/news/press/2001pres/2...
$428 Million

http://www3.niaid.nih.gov/news/newsrelea...
$232 Million

Now SIGA does not compete with vaccines, the government will stockpile both. I want to point out SIGA does also have a vaccine in developement if I am not mistaken?

SIGA has orphan drug status & that means exclusive marketing rights for 7 years for its oral drug. This kind of contract should be worth more than Acambis contract. Acambis had a total of $877 million coming towards them at one time.

Problem with Acambis is the vaccine they developed could not last long so shelf life became an issue as smallpox drugs are to be stockpiled to hedge bets against a bio-terrorist attack.

SIGA's dry oral jas no problem in that area. They will be restocking the shelves when the drug does get old.

Anyway we are just rehashing things. Bottom line SIGA should trade up to over $20 a share & maybe much higher on the first big contract. If SIGA gets angry enough at Pharma maybe they will let Wythe buy them out. Wythe was involved with smallpox vaccines in the past.

Why would anyone buy SIGA:

SIGA's antibiotic program addresses each of the major classes of antibiotics, a worldwide market of $24 billion annually. SIGA’s approach is aimed at disabling or eliminating the surface proteins bacteria use to attach to human tissue, the first step in the infection process. Since no existing antibiotics act through this mechanism, we believe this approach will be effective in addressing infections caused by drug-resistant bacteria.

SIGA is developing a novel class of antibiotics targeting Gram-positive bacteria. Gram-positive bacteria include Staphylococcus aureus, a major cause of hospital-acquired infections with treatment costs or more than $2 billion per year. SIGA’s antibiotic research team has also identified novel targets to be used in the development of new classes of both Gram-negative and broad–spectrum antibiotics.



Ich kann nur wiederholen laßt Euch nicht durch die Bascher und den aktuell gefallenen Kurs verunsichern in SIGA schlummert ein Milliarden Konzern.

Ich stocke weiter auf bei diesen Kursen und wette das ich mich nach 3-6 Monaten über solche Kurse wie wir Sie im Moment sehen kaputtlachen werde und froh bin das ich so günstig eingestiegen bin.

Hallo Kaufrausch1

Habe mir gestern ein paar ins Depot gelegt.

Gruß Noogmann

Zu Weihnachten noch dies:


http://finance.comcast.net/stocks/news_body.html?ID_NEWS=388…



Wir werden noch viel Spaß mit SIGA haben.

Hier mal ein Link zu einem Gespräch mit SIGA.


http://www.wallstreetreporter.com/profile.php?id=21271

Hier noch ein hilfreicher Link was Aktien angeht die teilweise short sind und gecovert werden müssen:

http://www.shortsqueeze.com/index.php?symbol=siga&submit=Ent…


Bei SIGA sind es 1,175,126 Aktien die short sind und die wollen sehr bald eingedeckt sein siehe Tabelle.

Ein Posting aus dem Yahoo-Board.


SIGA Technologies Inc. (SIGA)

CHART:

http://stockcharts.com/h-sc/ui?s=SIGA&p=D&b=5&g=0&id=p543794…

Price Support Pivot Point Resistance

3.75 3.55 3.76 3.97




BREAKOUT-WATCH

*********************************

4.84-5.60:

IBD Stock Checkup Analysis:
Siga Technologies Inc receives an overall rating of D, which is in the 45th percentile of all stocks in the Investor's Business Daily database. The overall rating is calculated using five proprietary ratings that measure each stock's Technical and Fundamental qualities and the Technical and Fundamental qualities of the industry group that it resides in, as well as a rating on the stock's current price attractiveness.

Siga Technologies Inc receives a Technical Rating of 51, which places it 80th out of 271 stocks in the Medical-Biomed/Biotech group.

Siga Technologies Inc receives a Fundamental Rating of 24, which places it 149th out of 271 stocks in the Medical-Biomed/Biotech group.

Siga Technologies Inc receives an Attractiveness Rating of 48, placing it 94th out of 271 stocks in its group.

The Medical-Biomed/Biotech group's technical rating of B ranks it in the 81st percentile of the 197 different Investor's Business Daily Industry Groups. The Medical-Biomed/Biotech group's fundamental rating is D-, ranking it in the 34th percentile of all groups.



IBD SmartSelect® Corporate Ratings
Earnings Per Share (EPS) Rating Relative Price Strength (RS) Rating Industry Group Relative Strength (Grp RS) Rating Sales + Profit Margins + ROE (SMR) Rating Accumulation/ Distribution (Acc/Dis) Rating
13 99 A+ E C-




Top Relative Strength Rating Tab


This IBD SmartSelect® Relative Strength Rating measures each stock's price performance over the latest twelve months compared to all other stocks. The rating scale ranges from 1 (lowest) to 99 (highest). Stocks rating below 70 indicate weaker relative price performance.

This tab in IBD's "Top Rated Stocks Under $10" product screens stocks for a Relative Strength Rating of 85 and higher.


A+



RANGE/RIDER:
RATINGS:
************************
Range Riders - Close cousins to the Rolling Stocks except that they tend to be more aggressive in an uptrend. They offer a better than average probability of success.







NAVELLIER"
********************
ALL STOCK GRADER SERVICES ARE 100%


http://www.navellier.com/stockgrader/

RATED=**SIGA***


""" B """""SWEET



Shares Outstanding:
31.77M

Shares Short
1.21M-PLUS




EINEN GUTEN RUTSCH INS NEUE JAHR ALLEN.

So dann kanns ja ab morgen losgehen was.

Hier ein Link zu den Researchs von SIGA.Einfach den Link anklicken und auf der Seite bei Symbol : SIGA eingeben.Es öffnet sich die Liste mit den Researchs.Der aktuellste ist vom 22.November.2006


http://adventfinancialinc.com/research_reports/index.php

Die angezeigte Pipeline auf Seite 4 ist schon beeindruckend.

Hallo Kaufrausch,
also...wenigstens ich lese Deine Infos und bin dankbar dafür, dass ich das nicht alles selbst suchen muss.

Grüsse B.

Es dauert nicht merh lange dann bricht Sie wieder nach oben aus.

http://pennystockpick.blogspot.com/2007/01/penny-stock-on-mo…

Antwort auf Beitrag Nr.: 26.705.704 von Kaufrausch1 am 06.01.07 02:33:38Hi Kaufrausch!

Sehr nette Kursrakete-Angebot! Ich habe aber ein Problem mit mein Depot. Die Ordereingabe mit "SIGA TECH.." verweigert sich. Das steht: fehlehafter oder nicht ausreichene Risikoklasse..

Welche Risikoklasse dürfen mit US-Aktie kaufen? Ich brauche eine Hilfe. Mein Risikoklasse steht "4" Ich habe nur Limit und Ordergültigkeit bis 15. Januar und Orderzusatz: Erster Kurs genommen.

Wo ist das Fehler?

Danke für ihre Mühe voraus!